FDA Approved: NEXLIZET — Original Application (Esperion Therapeutics, Inc.)

View source ↗

Summary

The FDA approved Nexlizet, a fixed-dose combination of bempedoic acid and ezetimibe, for adults with primary hyperlipidemia (including heterozygous familial hyp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Heterozygous Familial Hypercholesterolemia
• Hyperlipidemia

Drugs mentioned

• NEXLIZET (bempedoic acid and ezetimibe)

Snippet

ORIG AP for NEXLIZET (BEMPEDOIC ACID AND EZETIMIBE)